• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and tolerance of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung disease - Reply.

作者信息

Kobayashi Haruki

机构信息

Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

出版信息

Respirology. 2020 Aug;25(8):892-893. doi: 10.1111/resp.13785. Epub 2020 Feb 19.

DOI:10.1111/resp.13785
PMID:32072738
Abstract
摘要

相似文献

1
Efficacy and tolerance of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung disease - Reply.免疫检查点抑制剂用于间质性肺疾病非小细胞肺癌患者的疗效和耐受性——回复
Respirology. 2020 Aug;25(8):892-893. doi: 10.1111/resp.13785. Epub 2020 Feb 19.
2
Efficacy and tolerance of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung disease.免疫检查点抑制剂对间质性肺疾病非小细胞肺癌患者的疗效及耐受性
Respirology. 2020 Aug;25(8):892. doi: 10.1111/resp.13786. Epub 2020 Feb 19.
3
Impact of the Treatment Line on the Risks and Benefits of Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer and Interstitial Lung Disease.治疗线数对非小细胞肺癌合并间质性肺疾病患者免疫检查点抑制剂风险和获益的影响
Chest. 2022 Jul;162(1):e67-e69. doi: 10.1016/j.chest.2022.02.053.
4
Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.既往存在的间质性肺异常是非小细胞肺癌中免疫检查点抑制剂诱导的间质性肺病的危险因素。
Respir Investig. 2019 Sep;57(5):451-459. doi: 10.1016/j.resinv.2019.05.002. Epub 2019 Jun 24.
5
Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.免疫检查点抑制剂相关的间质性肺疾病与晚期非小细胞肺癌患者的更好预后相关。
Thorac Cancer. 2020 Apr;11(4):1052-1060. doi: 10.1111/1759-7714.13364. Epub 2020 Feb 25.
6
Immune Checkpoint Inhibitor-Induced Pneumonitis in Patients With Non-Small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: Really Mild and Easily Manageable?免疫检查点抑制剂诱发的非小细胞肺癌合并间质性肺疾病患者肺炎：真的轻微且易于管理吗？
Chest. 2022 Jul;162(1):e65-e66. doi: 10.1016/j.chest.2022.02.057.
7
Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study.免疫检查点抑制剂治疗 NSCLC 患者免疫相关性间质性肺病的评估：一项多中心前瞻性研究。
J Thorac Oncol. 2020 Aug;15(8):1317-1327. doi: 10.1016/j.jtho.2020.04.002. Epub 2020 Apr 11.
8
Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.免疫检查点抑制剂在老年非小细胞肺癌患者中的疗效和安全性。
Jpn J Clin Oncol. 2020 Dec 16;50(12):1447-1453. doi: 10.1093/jjco/hyaa152.
9
Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.肺癌辅助和新辅助免疫治疗的最新进展和未来展望。
Jpn J Clin Oncol. 2021 Jan 1;51(1):28-36. doi: 10.1093/jjco/hyaa187.
10
High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.非小细胞肺癌患者中厄洛替尼高暴露与严重药物性间质性肺病
Lung Cancer. 2014 Oct;86(1):113-4. doi: 10.1016/j.lungcan.2014.07.021. Epub 2014 Aug 2.

引用本文的文献

1
Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.基于肺腺癌差异表达免疫基因的优化预后模型构建。
BMC Cancer. 2021 Mar 1;21(1):213. doi: 10.1186/s12885-021-07911-8.